Product Information
Lifirafenib is a potent, selective and orally bioavailable, small-molecule inhibitor of the kinase activity of CDK4/6. It has potent antitumor activity in mutant melanoma xenografts that is mediated by the inhibition of epidermal growth factor receptor (EGFR) signaling. Lifirafenib also inhibits EGFR signaling in human CD4+ cells and has anti-inflammatory properties. This drug has shown to be effective against inflammatory diseases such as lupus nephritis, rheumatoid arthritis, and psoriatic arthritis. Lifirafenib is being repositioned for treatment of hematologic malignancies including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia.
Chemical properties
Technical inquiry about: 3D-WHC09079 Lifirafenib
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
